to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

Parkinson's Disease Clinical Trial

Official title:

An Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 After a Single Intramuscular Injection

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04593511
• Other study ID #: LY03009/CT-AUS-101
• Status: Enrolling by invitation
• Phase: Phase 1
• Start date: February 2, 2021
• Est. completion date: October 2021

Study information

• Verified date: June 2021
• Source: Luye Pharma Group Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers.

Description:

This is an open-label study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of four formulations of LY03009 (F1, F2, F3, F4) after a single intramuscular injection. Approximately 40 healthy subjects are planned to be enrolled in this study and assigned to four cohorts (F1, F2, F3, F4) sequentially, 10 subjects per group at a fixed dose of 112 mg for F1~F3 and 224 mg for F4. Each subject will receive only one dose in this study.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 40
• Est. completion date: October 2021
• Est. primary completion date: October 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

To participate in the study, subjects must meet all of the following inclusion criteria:

1. Willing and capable of giving signed written informed consent;

2. Male or female, 18-65 years of age (inclusive) at screening;

3. Body mass index (BMI, weight [kg]/height [m]2) between 18.0 and 30.0 kg/m2, inclusive;

4. The screening results within the normal range or outside the normal range but assessed as clinically non-significant by the Investigator based on detailed medical history, clinical laboratory tests, vital signs, physical examination, and 12-lead ECG; QTcF =450 msec for male subjects, and QTcF =470 msec for female subjects.

5. Males who are willing to remain abstinent; or if engaging in sexual intercourse with a female partner of childbearing potential, willing to use a condom in addition to having the female partner use a highly effective method of contraception throughout the study and until at least 3 months after the end of the study. This requirement does not apply to subjects in a same sex relationship or subjects with female partners of non-childbearing potential. Male subjects must also be willing to not donate sperm throughout the study and until at least 3 months after the end of the study. Exclusion Criteria:

Subjects meeting any of the following criteria will be excluded from the study:

1. With history of history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, neurologic, bronchopulmonary, immunologic, and/or lipid metabolism disorders, and/or drug hypersensitivity, or any other condition that, in the opinion of the PI, would jeopardize the safety of the subject, affect the validity of the study results, or impair the ability to provide informed consent;

2. Hospital admission or major surgery within 3 months prior to screening, or plan to have surgery before the completion of study;

3. Receipt of another investigational product within 1 month or 5 half-lives of the other investigational product, whichever is longer, before study drug administration in this study;

4. Unwillingness or inability to comply with food and beverage restrictions during study participation;

5. Have a history of significant drug sensitivity or drug allergy, or known hypersensitivity to the study drugs, the metabolite or formulation excipients;

6. Malignancy within 5 years of screening visit (excluding non-melanoma skin cancer and cervical carcinoma in situ that has been completely resected);

7. Subject who is considered unsuitable for participating in the study in the opinion of investigator.

8. Recent administration of live vaccine within 3 months prior to dosing and until at least 30 days after the completion of the study.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• LY03009 F1
a single dose of LY03009 F1
• LY03009 F2
a single dose of LY03009 F2
• LY03009 F3
a single dose of LY03009 F3
• LY03009 F4
a single dose of LY03009 F4

Locations

Country	Name	City	State
Australia	CMAX clinical Research Pty Ltd	Adelaide	South Australia

Sponsors (1)

Lead Sponsor	Collaborator
Luye Pharma Group Ltd.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of adverse events	Frequency of adverse events. Apply to cohort F1, cohort F2 and cohort F3.	From screening up to day 98
Primary	Frequency of adverse events	Frequency of adverse events. Apply to cohort F4.	From screening up to day 161
Secondary	Maximum (peak) plasma concentration (Cmax) of LY03009	Maximum (peak) plasma concentration (Cmax) of LY03009. Apply to cohort F1, cohort F2 and cohort F3.	From screening up to day 98
Secondary	Maximum (peak) plasma concentration (Cmax) of LY03009	Maximum (peak) plasma concentration (Cmax) of LY03009. Apply to cohort F4	From screening up to day 161
Secondary	Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of LY03009	Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of LY03009.Apply to cohort F1, cohort F2 and cohort F3.	From screening up to day 98
Secondary	Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of LY03009	Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of LY03009.Apply to cohort F4	From screening up to day 161
Secondary	Area under the plasma concentration-time curve from time zero to infinity (AUC0-8) of LY03009	Area under the plasma concentration-time curve from time zero to infinity (AUC0-8) of LY03009.Apply to cohort F1, cohort F2 and cohort F3.	From screening up to day 98
Secondary	Area under the plasma concentration-time curve from time zero to infinity (AUC0-8) of LY03009	Area under the plasma concentration-time curve from time zero to infinity (AUC0-8) of LY03009. Apply to cohort F4	From screening up to day 161
Secondary	Time to maximum plasma concentration (Tmax) of LY03009	Time to maximum plasma concentration (Tmax) of LY03009. Apply to cohort F1, cohort F2 and cohort F3.	From screening up to day 98
Secondary	Time to maximum plasma concentration (Tmax) of LY03009	Time to maximum plasma concentration (Tmax) of LY03009. Apply to cohort F4	From screening up to day 161
Secondary	Terminal elimination half-life (t1/2) of LY03009	Terminal elimination half-life (t1/2) of LY03009. Apply to cohort F1, cohort F2 and cohort F3.	From screening up to day 98
Secondary	Terminal elimination half-life (t1/2) of LY03009	Terminal elimination half-life (t1/2) of LY03009.Apply to cohort F4	From screening up to day 161
Secondary	Apparent clearance (CL/F) of LY03009	Apparent clearance (CL/F) of LY03009. Apply to cohort F1, cohort F2 and cohort F3.	From screening up to day 98
Secondary	Apparent clearance (CL/F) of LY03009	Apparent clearance (CL/F) of LY03009. Apply to cohort F4	From screening up to day 161
Secondary	Apparent volume of distribution (Vz/F) of LY03009	Apparent volume of distribution (Vz/F) of LY03009. Apply to cohort F1, cohort F2 and cohort F3.	From screening up to day 98
Secondary	Apparent volume of distribution (Vz/F) of LY03009	Apparent volume of distribution (Vz/F) of LY03009. Apply to cohort F4	From screening up to day 161
Secondary	Terminal elimination rate constant (?z) of LY03009	Terminal elimination rate constant (?z) of LY03009. Apply to cohort F1, cohort F2 and cohort F3.	From screening up to day 98
Secondary	Terminal elimination rate constant (?z) of LY03009	Terminal elimination rate constant (?z) of LY03009. Apply to cohort F4	From screening up to day 161
Secondary	Mean residence time (MRT) of LY03009	Mean residence time (MRT) of LY03009. Apply to cohort F1, cohort F2 and cohort F3.	From screening up to day 98
Secondary	Mean residence time (MRT) of LY03009	Mean residence time (MRT) of LY03009. Apply to cohort F4	From screening up to day 161
Secondary	Area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total AUC (%AUCex) of LY03009	Area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total AUC (%AUCex) of LY03009. Apply to cohort F1, cohort F2 and cohort F3.	From screening up to day 98
Secondary	Area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total AUC (%AUCex) of LY03009	Area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total AUC (%AUCex) of LY03009. Apply to cohort F4	From screening up to day 161